Shares of OptimizeRx Co. (NASDAQ:OPRX) have received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus target price of $25.88 for the company and are expecting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also given OptimizeRx an industry rank of 84 out of 256 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of OptimizeRx from a “hold” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research note on Tuesday, May 14th.
A number of institutional investors have recently modified their holdings of OPRX. BlackRock Inc. bought a new stake in shares of OptimizeRx in the 4th quarter valued at about $55,000. Timpani Capital Management LLC raised its holdings in shares of OptimizeRx by 51.5% in the 4th quarter. Timpani Capital Management LLC now owns 108,643 shares of the company’s stock valued at $1,192,000 after purchasing an additional 36,949 shares in the last quarter. Northern Trust Corp raised its holdings in shares of OptimizeRx by 71.5% in the 4th quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock valued at $192,000 after purchasing an additional 7,283 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in shares of OptimizeRx in the 4th quarter valued at about $289,000. Finally, Avenir Corp raised its holdings in shares of OptimizeRx by 74.2% in the 4th quarter. Avenir Corp now owns 117,400 shares of the company’s stock valued at $1,288,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 48.47% of the company’s stock.
Shares of NASDAQ OPRX traded up $0.14 during trading hours on Wednesday, hitting $16.21. 45,749 shares of the stock were exchanged, compared to its average volume of 81,880. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a market capitalization of $194.45 million, a P/E ratio of 326.20, a PEG ratio of 1.87 and a beta of 0.51. The firm’s fifty day simple moving average is $14.95. OptimizeRx has a 12 month low of $8.92 and a 12 month high of $18.39.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Article: Stock Symbol
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.